
    
      Study Design: This open label, multicenter, first in human study consists of 2 parts. Part 1
      is a dose escalation to find the recommended dose for the expansion.

      Part 2 is a dose expansion to confirm the dose of MCLA-145 through further evaluation of
      safety, tolerability, Pk, preliminary antitumor activity, and functional target engagement.

      The study includes three periods: Screening( up to 28 days prior to the first dose of study
      drug); Treatment( first dose of study drug with treatment cycles of 28 days); and Follow-up (
      30 days and 90 days after the last dose) including survival follow-up checks every 2 months
      up to 12 months after the last dose.
    
  